Related references
Note: Only part of the references are listed.Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union
Jarno Hoekman et al.
SOCIAL SCIENCE & MEDICINE (2019)
Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
Huseyin Naci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU
Jarno Hoekman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
Michael Ermisch et al.
Frontiers in Pharmacology (2016)
Use of the Conditional Marketing Authorization Pathway for Oncology Medicines in Europe
J. Hoekman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Does Conditional Approval for New Oncology Drugs in Europe Lead to Differences in Health Technology Assessment Decisions?
I. Lipska et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Approvals of drugs with uncertain benefit-risk profiles in Europe
Rita Banzi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2015)
Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
Alessandra Ferrario et al.
SOCIAL SCIENCE & MEDICINE (2015)
Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions A Comparison of Britain, Australia, and Canada
Fiona M. Clement et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Comparative Effectiveness Research and Evidence-Based Health Policy: Experience from Four Countries
Kalipso Chalkidou et al.
MILBANK QUARTERLY (2009)
Share Paper
